News Quantified

TARA – protara therapeutics, inc. (US:NASDAQ)

Protara Therapeutics (TARA) had its "buy" rating reaffirmed by TD Cowen.

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Protara Therapeutics (TARA) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $27.00 price target on the stock.

Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf [Yahoo! Finance]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}